Living in today’s world we have made tremendous gains within modern medicine. Creating new remedies that help fight and treat numerous forms of illnesses and diseases. Bristol-Myers Squibb (BMY), a company that discovers, develops, licenses, manufactures, and markets, distributes, and sells biopharmaceutical products worldwide. BMY has released a statement announcing that the European Commission has approved YERVOYTM (ipilimumab), a remedy for previously treated cases of severe melanoma.
YERVOY is an ingenious immunotherapy. YERVOY displays long-term survival in the treatment of individuals with severe melanoma in a randomized, double blind Phase III study that was published in the New England Journal of Medicine in June 2010.
Going off the survival stats, patients treated with YERVOY have an estimated 1 and 2 years of living from a 46% and 24% ratio, respectively vs. 25% and 14%.
“With the approval of YERVOY physicians now have an important new option to offer to patients with metastatic melanoma. This is a chance of not just months but potentially 3 to 4 years of prolonged survival for some patients in the treatment of metastatic melanoma,” stated by Professor Alexander Eggermont, General Director, Institute Gustave Roussy, Paris, France. “There is hope that YERVOY’s novel mode of action, together with the fact that the recommended complete course of treatment with YERVOY (3 mg/kg) includes 4 infusions over 3 months, could potentially change the way we treat patients with previously treated advanced melanoma. It is an example of what can be done through unleashing the power of one’s own immune response.”
Bristol-Myers Squibb will now be working along side wit local health officials to accelerate the availability of YERVOY all throughout the European Union.
With innovative breakthroughs like YERVOY we can only imagine what the progression of the biotech industry will look like in the future.